NCT05279300: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with triple negative breast cancer are also eligible for the dose expansion phase
Exclusions: Patients without at least 2 lines of systemic therapy for advanced disease; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; For TNBC patients – any prior exposure to therapies targeting ROR1

Comments are closed.

Up ↑